Sanofi Starts Late-Stage Trial of Eliglustat for Gaucher Disease

Jan. 26 (Bloomberg) -- Sanofi said it’s starting the last of three stages of human testing for its experimental pill for Gaucher disease, a rare genetic illness.

Results from the second phase of testing for the pill, called eliglustat, will be presented next month, said Marisol Peron, a Sanofi spokeswoman, in an interview.

To contact the reporter on this story: Trista Kelley in London at tkelley2@bloomberg.net

To contact the editor responsible for this story: Kristen Hallam at khallam@bloomberg.net